Stammdaten
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Unternehmen & Branche
| Name | Nautilus Biotechnology, Inc. |
|---|---|
| Ticker | NAUT |
| CIK | 0001808805 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 3826 · Laboratory Analytical Instruments |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 312,6 Mio. USD |
| Beta | 0,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -59,001,000 | -0.47 | 191,112,000 | 156,973,000 | |
| 2025-09-30 | 10-Q | -13,574,000 | -0.11 | 200,915,000 | 169,139,000 | |
| 2025-06-30 | 10-Q | -15,033,000 | -0.12 | 213,189,000 | 181,094,000 | |
| 2025-03-31 | 10-Q | -16,613,000 | -0.13 | 227,690,000 | 194,435,000 | |
| 2024-12-31 | 10-K | -70,780,000 | -0.56 | 242,743,000 | 208,730,000 | |
| 2024-09-30 | 10-Q | -16,446,000 | -0.13 | 259,704,000 | 223,434,000 | |
| 2024-06-30 | 10-Q | -18,010,000 | -0.14 | 272,747,000 | 235,279,000 | |
| 2024-03-31 | 10-Q | -18,730,000 | -0.15 | 288,650,000 | 249,492,000 | |
| 2023-12-31 | 10-K | -63,675,000 | -0.51 | 305,565,000 | 265,353,000 | |
| 2023-09-30 | 10-Q | -15,878,000 | -0.13 | 318,336,000 | 277,273,000 | |
| 2023-06-30 | 10-Q | -15,808,000 | -0.13 | 330,767,000 | 289,673,000 | |
| 2023-03-31 | 10-Q | -14,965,000 | -0.12 | 345,884,000 | 303,715,000 | |
| 2022-12-31 | 10-K | -57,924,000 | -0.46 | 350,052,000 | 314,924,000 | |
| 2022-09-30 | 10-Q | -14,063,000 | -0.11 | 359,307,000 | 325,338,000 | |
| 2022-06-30 | 10-Q | -14,689,000 | -0.12 | 371,707,000 | 337,558,000 | |
| 2022-03-31 | 10-Q | -15,763,000 | -0.13 | 384,673,000 | 349,709,000 | |
| 2021-12-31 | 10-K | -50,315,000 | -0.60 | 398,450,000 | 363,576,000 | |
| 2021-09-30 | 10-Q | -14,504,000 | -0.12 | 385,347,000 | 377,847,000 | |
| 2021-06-30 | 10-Q | -10,713,000 | -0.19 | 393,275,000 | 390,044,000 | |
| 2021-03-31 | 10-Q | -8,409,000 | -0.25 | 150,499,574 | -36,795,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Patel Sujal M | Director, Officer, 10% Owner, CEO, President, and Secretary | Open Market Purchase | 25,000 | 2.61 | 65,237.50 | +216,6% | |
| 2025-11-06 | Suzuki Kentaro | Officer, Chief Marketing Officer | Open Market Purchase | 4,000 | 1.49 | 5,960.00 | +19,8% | |
| 2025-09-08 | Patel Sujal M | Director, Officer, 10% Owner, CEO, President, and Secretary | Open Market Purchase | 83,500 | 0.68 | 57,030.50 | +189,3% | |
| 2025-09-05 | Patel Sujal M | Director, Officer, 10% Owner, CEO, President, and Secretary | Open Market Purchase | 116,500 | 0.67 | 78,544.30 | +260,7% | |
| 2025-09-04 | Murphy Matthew B. | Officer, General Counsel | Open Market Purchase | 20,000 | 0.64 | 12,858.00 | +42,7% | |
| 2025-05-29 | Mowry Anna | Officer, CFO and Treasurer | Open Market Purchase | 15,000 | 0.77 | 11,488.50 | +38,1% | |
| 2025-05-12 | Mallick Parag | Director, Officer, 10% Owner, Chief Scientist | Open Market Purchase | 1,500 | 0.73 | 1,097.55 | +3,6% | |
| 2025-05-08 | Mallick Parag | Director, Officer, 10% Owner, Chief Scientist | Open Market Purchase | 12,000 | 0.73 | 8,787.60 | +29,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.